Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Forasartan | Mebutizide may increase the hypotensive and Electrolyte Disturbance activities of Forasartan. |
| Tasosartan | Mebutizide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan. |
| Saralasin | Mebutizide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Fimasartan | Mebutizide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan. |
| Nicotine | The risk or severity of adverse effects can be increased when Mebutizide is combined with Nicotine. |
| Cyclopentamine | The risk or severity of adverse effects can be increased when Mebutizide is combined with Cyclopentamine. |
| Methotrexate | The protein binding of Methotrexate can be increased when combined with Mebutizide. |
| Calcitriol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Calcitriol. |
| Calcifediol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Calcifediol. |
| Ergocalciferol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Ergocalciferol. |
| Cholecalciferol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Cholecalciferol. |
| Paricalcitol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Paricalcitol. |
| Dihydrotachysterol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Dihydrotachysterol. |
| Alfacalcidol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Alfacalcidol. |
| Seocalcitol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Seocalcitol. |
| Inecalcitol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Inecalcitol. |
| Becocalcidiol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Becocalcidiol. |
| Eldecalcitol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Eldecalcitol. |
| 1alpha,24S-Dihydroxyvitamin D2 | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with 1alpha,24S-Dihydroxyvitamin D2. |
| Elocalcitol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Elocalcitol. |
| Maxacalcitol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Maxacalcitol. |
| Doxercalciferol | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Doxercalciferol. |
| Vitamin D | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Vitamin D. |
| 1alpha-Hydroxyvitamin D5 | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with 1alpha-Hydroxyvitamin D5. |
| Previtamin D(3) | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Previtamin D(3). |
| Dexketoprofen | The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mebutizide. |
| Ketoprofen | The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mebutizide. |
| Cyclosporine | The risk or severity of renal failure can be increased when Mebutizide is combined with Cyclosporine. |
| Insulin glargine | The risk or severity of hypoglycemia can be increased when Mebutizide is combined with Insulin glargine. |
| Insulin detemir | The risk or severity of hypoglycemia can be increased when Mebutizide is combined with Insulin detemir. |
| Insulin tregopil | The risk or severity of hypoglycemia can be increased when Mebutizide is combined with Insulin tregopil. |
| Ipragliflozin | The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Mebutizide. |
| Allicin | The therapeutic efficacy of Allicin can be decreased when used in combination with Mebutizide. |
| Tofogliflozin | The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Mebutizide. |
| Ertugliflozin | The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Mebutizide. |
| Remogliflozin etabonate | The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Mebutizide. |
| Tirzepatide | The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Mebutizide. |
| Gastric inhibitory polypeptide | The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Mebutizide. |
| Colestipol | Colestipol can cause a decrease in the absorption of Mebutizide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sevelamer | Sevelamer can cause a decrease in the absorption of Mebutizide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Colesevelam | Colesevelam can cause a decrease in the absorption of Mebutizide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cholestyramine | Cholestyramine can cause a decrease in the absorption of Mebutizide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium phosphate, monobasic | Mebutizide may increase the nephrotoxic activities of Sodium phosphate, monobasic. |
| Acemetacin | The therapeutic efficacy of Mebutizide can be decreased when used in combination with Acemetacin. |
| Lactulose | The risk or severity of dehydration can be increased when Mebutizide is combined with Lactulose. |
| Magnesium sulfate | The risk or severity of dehydration can be increased when Mebutizide is combined with Magnesium sulfate. |
| Mannitol | The risk or severity of dehydration can be increased when Mebutizide is combined with Mannitol. |
| Lubiprostone | The risk or severity of dehydration can be increased when Mebutizide is combined with Lubiprostone. |
| Tegaserod | The risk or severity of dehydration can be increased when Mebutizide is combined with Tegaserod. |
| Magnesium oxide | The risk or severity of dehydration can be increased when Mebutizide is combined with Magnesium oxide. |
| Magnesium cation | The risk or severity of dehydration can be increased when Mebutizide is combined with Magnesium cation. |
| Sorbitol | The risk or severity of dehydration can be increased when Mebutizide is combined with Sorbitol. |
| Dantron | The risk or severity of dehydration can be increased when Mebutizide is combined with Dantron. |
| Oxyphenisatin | The risk or severity of dehydration can be increased when Mebutizide is combined with Oxyphenisatin. |
| Phenolphthalein | The risk or severity of dehydration can be increased when Mebutizide is combined with Phenolphthalein. |
| Prucalopride | The risk or severity of dehydration can be increased when Mebutizide is combined with Prucalopride. |
| Emodin | The risk or severity of dehydration can be increased when Mebutizide is combined with Emodin. |
| Linaclotide | The risk or severity of dehydration can be increased when Mebutizide is combined with Linaclotide. |
| Bisacodyl | The risk or severity of dehydration can be increased when Mebutizide is combined with Bisacodyl. |
| Magnesium hydroxide | The risk or severity of dehydration can be increased when Mebutizide is combined with Magnesium hydroxide. |
| Bisoxatin | The risk or severity of dehydration can be increased when Mebutizide is combined with Bisoxatin. |
| Picosulfuric acid | The risk or severity of dehydration can be increased when Mebutizide is combined with Picosulfuric acid. |
| Magnesium trisilicate | The risk or severity of dehydration can be increased when Mebutizide is combined with Magnesium trisilicate. |
| Polyethylene glycol | The risk or severity of dehydration can be increased when Mebutizide is combined with Polyethylene glycol. |
| Polycarbophil | The risk or severity of dehydration can be increased when Mebutizide is combined with Polycarbophil. |
| Magnesium acetate tetrahydrate | The risk or severity of dehydration can be increased when Mebutizide is combined with Magnesium acetate tetrahydrate. |
| Monopotassium phosphate | The risk or severity of dehydration can be increased when Mebutizide is combined with Monopotassium phosphate. |
| Dipotassium phosphate | The risk or severity of dehydration can be increased when Mebutizide is combined with Dipotassium phosphate. |
| Glycerin | The risk or severity of dehydration can be increased when Mebutizide is combined with Glycerin. |
| Sodium sulfate | The risk or severity of dehydration can be increased when Mebutizide is combined with Sodium sulfate. |
| Magnesium carbonate | The risk or severity of dehydration can be increased when Mebutizide is combined with Magnesium carbonate. |
| Potassium lactate | The risk or severity of dehydration can be increased when Mebutizide is combined with Potassium lactate. |
| Sodium fluorophosphate | The risk or severity of dehydration can be increased when Mebutizide is combined with Sodium fluorophosphate. |
| Mineral oil | The risk or severity of dehydration can be increased when Mebutizide is combined with Mineral oil. |
| Carboxymethylcellulose | The risk or severity of dehydration can be increased when Mebutizide is combined with Carboxymethylcellulose. |
| Docusate | The risk or severity of dehydration can be increased when Mebutizide is combined with Docusate. |
| Plantago seed | The risk or severity of dehydration can be increased when Mebutizide is combined with Plantago seed. |
| Magnesium citrate | The risk or severity of dehydration can be increased when Mebutizide is combined with Magnesium citrate. |
| Castor oil | The risk or severity of dehydration can be increased when Mebutizide is combined with Castor oil. |
| Magnesium glycinate | The risk or severity of dehydration can be increased when Mebutizide is combined with Magnesium glycinate. |
| Methylcellulose | The risk or severity of dehydration can be increased when Mebutizide is combined with Methylcellulose. |
| Sennosides | The risk or severity of dehydration can be increased when Mebutizide is combined with Sennosides. |
| Lactitol | The risk or severity of dehydration can be increased when Mebutizide is combined with Lactitol. |
| Plecanatide | The risk or severity of dehydration can be increased when Mebutizide is combined with Plecanatide. |
| Gluconic Acid | The risk or severity of dehydration can be increased when Mebutizide is combined with Gluconic Acid. |
| Magnesium peroxide | The risk or severity of dehydration can be increased when Mebutizide is combined with Magnesium peroxide. |
| Pentaerithrityl | The risk or severity of dehydration can be increased when Mebutizide is combined with Pentaerithrityl. |
| Sodium tartrate | The risk or severity of dehydration can be increased when Mebutizide is combined with Sodium tartrate. |
| Magnesium acetate | The risk or severity of dehydration can be increased when Mebutizide is combined with Magnesium acetate. |
| Deacetylbisacodyl | The risk or severity of dehydration can be increased when Mebutizide is combined with Deacetylbisacodyl. |
| Sodium ascorbate | The risk or severity of dehydration can be increased when Mebutizide is combined with Sodium ascorbate. |
| Potassium sulfate | The risk or severity of dehydration can be increased when Mebutizide is combined with Potassium sulfate. |
| Sodium phosphate, dibasic | The risk or severity of dehydration can be increased when Mebutizide is combined with Sodium phosphate, dibasic. |
| Sodium phosphate, monobasic, unspecified form | The risk or severity of dehydration can be increased when Mebutizide is combined with Sodium phosphate, monobasic, unspecified form. |
| Sodium phosphate, dibasic, unspecified form | The risk or severity of dehydration can be increased when Mebutizide is combined with Sodium phosphate, dibasic, unspecified form. |
| Sodium cation | The risk or severity of dehydration can be increased when Mebutizide is combined with Sodium cation. |
| Plantago ovata seed | The risk or severity of dehydration can be increased when Mebutizide is combined with Plantago ovata seed. |
| Oxyphenisatin acetate | The risk or severity of dehydration can be increased when Mebutizide is combined with Oxyphenisatin acetate. |
| Calcium polycarbophil | The risk or severity of dehydration can be increased when Mebutizide is combined with Calcium polycarbophil. |
| Konjac mannan | The risk or severity of dehydration can be increased when Mebutizide is combined with Konjac mannan. |